ALSO NOTED: BioVeris to collaborate with UMass; Genentech seeks expanded Rituxan use; Antisoma wins orphan status; and much mor

> BioVeris is collaborating with researchers at the University of Massachusetts to find a vaccine for chlamydia. BioVeris will have exclusive patent rights and UMass gets $600,000 in research funds. Report

> Genentech and Biogen Idec are seeking expanded use of Rituxan. Release

> The UK's Antisoma announced that the FDA had given its experimental drug for renal cancer orphan drug status. Story

> Australia's Giaconda hopes to raise $6 million in an IPO. Story

> Genstruct has reached its first milestone with Pfizer. Release

> Lundbeck's operating profits have fallen. Story

And Finally… Oregon has implemented a new law that requires a prescription for most cold remedies that can be used to make methamphetamines. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.